source
- FDA advisory panel finds Grail's Galleri multicancer blood test benefits outweigh risksA Food and Drug Administration advisory panel voted 7-2, with one abstention, to conclude that the probable benefits of Grail's Galleri multicancer blood test outweigh its risks. The panel unanimou…
- Henlius Biotech signs $440 million deal with Amberstone to develop T-cell engagersHenlius Biotech, a subsidiary of Fosun Pharma, announced a licensing agreement with California‑based Amberstone Biosciences valued at up to $440 million. The partnership will focus on creating anti…